SE441357B - 4-pyridino - cyanoguanidinderivat, forfarande for framstellning av detta samt en komposition med blodtryckssenkande verkan - Google Patents
4-pyridino - cyanoguanidinderivat, forfarande for framstellning av detta samt en komposition med blodtryckssenkande verkanInfo
- Publication number
- SE441357B SE441357B SE8205107A SE8205107A SE441357B SE 441357 B SE441357 B SE 441357B SE 8205107 A SE8205107 A SE 8205107A SE 8205107 A SE8205107 A SE 8205107A SE 441357 B SE441357 B SE 441357B
- Authority
- SE
- Sweden
- Prior art keywords
- acid
- compound
- group
- salt
- cyano
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 16
- 238000000034 method Methods 0.000 title claims description 14
- 230000000694 effects Effects 0.000 title description 9
- 239000004615 ingredient Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 40
- 150000003839 salts Chemical class 0.000 claims description 14
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 12
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 9
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000003276 anti-hypertensive effect Effects 0.000 claims description 7
- 239000012429 reaction media Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 238000006213 oxygenation reaction Methods 0.000 claims description 5
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 claims description 4
- 231100000252 nontoxic Toxicity 0.000 claims description 4
- 230000003000 nontoxic effect Effects 0.000 claims description 4
- 230000003647 oxidation Effects 0.000 claims description 4
- 238000007254 oxidation reaction Methods 0.000 claims description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- YNJSNEKCXVFDKW-UHFFFAOYSA-N 3-(5-amino-1h-indol-3-yl)-2-azaniumylpropanoate Chemical compound C1=C(N)C=C2C(CC(N)C(O)=O)=CNC2=C1 YNJSNEKCXVFDKW-UHFFFAOYSA-N 0.000 claims description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 2
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 2
- 229910052804 chromium Inorganic materials 0.000 claims description 2
- 239000011651 chromium Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- PEYVWSJAZONVQK-UHFFFAOYSA-N hydroperoxy(oxo)borane Chemical compound OOB=O PEYVWSJAZONVQK-UHFFFAOYSA-N 0.000 claims description 2
- 229910052750 molybdenum Inorganic materials 0.000 claims description 2
- 239000011733 molybdenum Substances 0.000 claims description 2
- JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- XMVONEAAOPAGAO-UHFFFAOYSA-N sodium tungstate Chemical compound [Na+].[Na+].[O-][W]([O-])(=O)=O XMVONEAAOPAGAO-UHFFFAOYSA-N 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 claims description 2
- 229910052721 tungsten Inorganic materials 0.000 claims description 2
- 239000010937 tungsten Substances 0.000 claims description 2
- 229910052720 vanadium Inorganic materials 0.000 claims description 2
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 3
- 125000001931 aliphatic group Chemical group 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 239000007800 oxidant agent Substances 0.000 claims 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- -1 1-ethyl-1-methylpropyl Chemical group 0.000 claims 1
- SDYSNRRRDUJUAS-UHFFFAOYSA-N 2-(3,3-dimethylbutyl)guanidine Chemical compound CC(C)(C)CCN=C(N)N SDYSNRRRDUJUAS-UHFFFAOYSA-N 0.000 claims 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 229910052748 manganese Inorganic materials 0.000 claims 1
- 239000011572 manganese Substances 0.000 claims 1
- 150000007522 mineralic acids Chemical class 0.000 claims 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 239000008187 granular material Substances 0.000 description 9
- 238000001914 filtration Methods 0.000 description 8
- 239000012043 crude product Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 230000001706 oxygenating effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000001632 sodium acetate Substances 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- HKCIAYNSNFLSIC-UHFFFAOYSA-N 2-benzyl-1-cyano-3-pyridin-4-ylguanidine Chemical compound C=1C=CC=CC=1CN=C(NC#N)NC1=CC=NC=C1 HKCIAYNSNFLSIC-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000004531 blood pressure lowering effect Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- 125000005919 1,2,2-trimethylpropyl group Chemical group 0.000 description 1
- CZNIFFZKJQUHKS-UHFFFAOYSA-N 1-cyano-1-pyridin-4-ylguanidine Chemical class NC(=N)N(C#N)C1=CC=NC=C1 CZNIFFZKJQUHKS-UHFFFAOYSA-N 0.000 description 1
- BWMDMTSNSXYYSP-UHFFFAOYSA-N 2-propylguanidine Chemical compound CCCNC(N)=N BWMDMTSNSXYYSP-UHFFFAOYSA-N 0.000 description 1
- QWMFKVNJIYNWII-UHFFFAOYSA-N 5-bromo-2-(2,5-dimethylpyrrol-1-yl)pyridine Chemical compound CC1=CC=C(C)N1C1=CC=C(Br)C=N1 QWMFKVNJIYNWII-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000004966 inorganic peroxy acids Chemical class 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000004967 organic peroxy acids Chemical class 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8127367 | 1981-09-10 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE8205107D0 SE8205107D0 (sv) | 1982-09-08 |
| SE8205107L SE8205107L (sv) | 1983-03-11 |
| SE441357B true SE441357B (sv) | 1985-09-30 |
Family
ID=10524416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8205107A SE441357B (sv) | 1981-09-10 | 1982-09-08 | 4-pyridino - cyanoguanidinderivat, forfarande for framstellning av detta samt en komposition med blodtryckssenkande verkan |
Country Status (16)
| Country | Link |
|---|---|
| JP (1) | JPS5857363A (en]) |
| BE (1) | BE894350A (en]) |
| CA (1) | CA1177080A (en]) |
| CH (1) | CH655500B (en]) |
| DE (1) | DE3233380A1 (en]) |
| DK (1) | DK157923C (en]) |
| FR (1) | FR2512447B1 (en]) |
| GB (1) | GB2105331B (en]) |
| GR (1) | GR77009B (en]) |
| IE (1) | IE54196B1 (en]) |
| IT (1) | IT1156515B (en]) |
| LU (1) | LU84375A1 (en]) |
| NL (1) | NL8203214A (en]) |
| PH (1) | PH18596A (en]) |
| SE (1) | SE441357B (en]) |
| ZA (1) | ZA825997B (en]) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5371086A (en) * | 1991-03-15 | 1994-12-06 | The Green Cross Corporation | Aminopyridine compounds |
| JPH05294935A (ja) * | 1991-03-15 | 1993-11-09 | Green Cross Corp:The | アミノピリジン系化合物 |
| WO2007022946A1 (de) | 2005-08-21 | 2007-03-01 | Abbott Gmbh & Co. Kg | Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren |
| US9296697B2 (en) | 2005-08-24 | 2016-03-29 | Abbott Laboratories | Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3074955A (en) * | 1960-11-30 | 1963-01-22 | Us Vitamin Pharm Corp | Pyridylalkyl dicyandiamides and guanylureas |
| US3329569A (en) * | 1962-07-31 | 1967-07-04 | Smith Kline French Lab | Hypotensive compositions and methods of producing hypotension |
| FR2043491A1 (en) * | 1969-05-30 | 1971-02-19 | Ugine Kuhlmann | Alpha-pyrid-4'-yl-benzylidene-aminoguani- - dines useful as hypotensives and spasmoly-tics |
| GB1489879A (en) * | 1974-12-20 | 1977-10-26 | Leo Pharm Prod Ltd | N'-cyano-n'-3-pyridylguanidines |
| NL8000869A (nl) * | 1979-02-16 | 1980-08-19 | Eisai Co Ltd | Cyanoguanidine-derivaten en werkwijze voor de bereiding daarvan. |
-
1982
- 1982-08-09 IE IE1918/82A patent/IE54196B1/en unknown
- 1982-08-16 PH PH27732A patent/PH18596A/en unknown
- 1982-08-16 NL NL8203214A patent/NL8203214A/nl not_active Application Discontinuation
- 1982-08-18 ZA ZA825997A patent/ZA825997B/xx unknown
- 1982-08-31 CH CH517782A patent/CH655500B/de not_active IP Right Cessation
- 1982-08-31 GB GB08224808A patent/GB2105331B/en not_active Expired
- 1982-09-07 DK DK398882A patent/DK157923C/da not_active IP Right Cessation
- 1982-09-07 CA CA000410917A patent/CA1177080A/en not_active Expired
- 1982-09-08 GR GR69232A patent/GR77009B/el unknown
- 1982-09-08 SE SE8205107A patent/SE441357B/sv not_active IP Right Cessation
- 1982-09-08 DE DE19823233380 patent/DE3233380A1/de not_active Withdrawn
- 1982-09-09 IT IT68075/82A patent/IT1156515B/it active
- 1982-09-09 BE BE0/208978A patent/BE894350A/fr not_active IP Right Cessation
- 1982-09-09 FR FR8215312A patent/FR2512447B1/fr not_active Expired
- 1982-09-09 JP JP57157939A patent/JPS5857363A/ja active Pending
- 1982-09-09 LU LU84375A patent/LU84375A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB2105331B (en) | 1985-05-01 |
| DK398882A (da) | 1983-03-11 |
| IT8268075A0 (it) | 1982-09-09 |
| BE894350A (fr) | 1983-03-09 |
| SE8205107L (sv) | 1983-03-11 |
| JPS5857363A (ja) | 1983-04-05 |
| PH18596A (en) | 1985-08-15 |
| IT1156515B (it) | 1987-02-04 |
| ZA825997B (en) | 1983-07-27 |
| CA1177080A (en) | 1984-10-30 |
| IE54196B1 (en) | 1989-07-19 |
| NL8203214A (nl) | 1983-04-05 |
| GR77009B (en]) | 1984-09-04 |
| IE821918L (en) | 1983-03-10 |
| DK157923B (da) | 1990-03-05 |
| GB2105331A (en) | 1983-03-23 |
| CH655500B (en]) | 1986-04-30 |
| SE8205107D0 (sv) | 1982-09-08 |
| LU84375A1 (fr) | 1983-06-07 |
| DE3233380A1 (de) | 1983-03-17 |
| FR2512447B1 (fr) | 1985-11-22 |
| DK157923C (da) | 1990-08-06 |
| FR2512447A1 (fr) | 1983-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4450159A (en) | Carbamic acid derivatives as selective immunosuppresive agents | |
| DE68924221T2 (de) | Imidazolderivate. | |
| SE441357B (sv) | 4-pyridino - cyanoguanidinderivat, forfarande for framstellning av detta samt en komposition med blodtryckssenkande verkan | |
| WO2000051995A1 (de) | Polycyclische 2-amino-thiazol systeme, verfahren zu ihrer herstellung und arzneimittel enthaltend diese verbindungen | |
| JPS60126284A (ja) | ピリドンカルボン酸誘導体およびその塩 | |
| EP0008652A1 (de) | Neue Zwischenprodukte und deren Verwendung zur Herstellung von neuen Oxadiazolopyrimidinderivaten | |
| EP0326981B1 (de) | 4-Oxo-4H-pyrido[1,2-a]pyrimidin-3-carbonsäureamid-Derivate, deren Herstellung sowie diese Verbindungen enthaltende Arzneimittelpräparate und deren Herstellung | |
| EP1183247B1 (de) | Polycyclische thiazol-systeme und ihre verwendung als anorektika | |
| US3055910A (en) | Hydrazinonitrofurylthiazoles | |
| KR860000103B1 (ko) | 3'-치환-5'-(2-아미노-4-피리딜)-1', 2', 4'-트리아졸류의 제조 방법 | |
| DE4019080A1 (de) | Neue 3,7-diazabicycolo (3,3,1)nonan-verbindungen enthaltende arzneimittel | |
| EP0088323B1 (de) | Imidazothiadiazolalkencarbonsäureamide, neue Zwischenprodukte zu ihrer Herstellung, ihre Herstellung und ihre Verwendung in Arzneimitteln | |
| US4352929A (en) | 1,3-Thiazin-4-one | |
| DE60013607T2 (de) | Bemzimidazolverbindungen und medikamente die diese enthalten | |
| DE3876859T2 (de) | Cardiotonische tricyclische oxazolone. | |
| DE2520131A1 (de) | Stickstoffhaltige polycyclische verbindungen und verfahren zu deren herstellung | |
| CH648022A5 (de) | 1(2h)-isochinolon-verbindungen und saeureadditionssalze davon. | |
| CH648558A5 (de) | 1,1-disubstituierte octahydroindolo(2,3-a)chinolizine, diese verbindungen enthaltendes arzneimittel sowie verfahren zu ihrer herstellung. | |
| AT351517B (de) | Verfahren zur herstellung von neuen aminoalkyl- phenoxyalkansaeuren und deren salzen | |
| AT351540B (de) | Verfahren zur herstellung von neuen tetrahydro- isochinolinderivaten und deren salzen | |
| AT273964B (de) | Verfahren zur Herstellung von neuen benzheterocyclischen Verbindungen und ihren Salzen | |
| DE2753391A1 (de) | Benzisothiazolone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneipraeparate | |
| DE4216028A1 (de) | 2-(Substituierte Imino)-thiazolidin-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel sowie ihre Verwendung | |
| WO1996003403A1 (de) | Benzylimidazopyridine | |
| AT355038B (de) | Verfahren zur herstellung von neuen veraetherten hydroxy-benzimidazolonen, -benzoxazolonen, - -benzoxazinonen, -chinazolinonen und- chino- xazolinonen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |
Ref document number: 8205107-9 Effective date: 19920502 Format of ref document f/p: F |